Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 27, 2003
La Jolla Pharmaceutical Company
Delaware | 0-24274 | 33-0361285 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
6455 Nancy Ridge Drive, San Diego, California | 92121 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
N/A
Item 5. Other Events and Required FD Disclosure. | ||||||||
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EXHIBIT 99.1 |
Table of Contents
Item 5. Other Events and Required FD Disclosure.
On October 27, 2003, the Company issued a press release announcing that Matthew Linnik, Ph.D., the Company’s Chief Scientific Officer and Executive Vice President of Research, and several of the Company’s principal investigators, reviewed previously released data from several of the Company’s clinical trials of Riquent™ and data regarding LJP 1082 at the American College of Rheumatology 67th Annual Scientific Meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits. The following exhibits are filed with this report on Form 8-K:
Exhibit | ||
Number | Description of Exhibit | |
99.1 | Press Release |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LA JOLLA PHARMACEUTICAL COMPANY | ||||
Date: October 27, 2003 | By: | /s/ Gail A. Sloan | ||
Gail A. Sloan Senior Director of Finance and Controller |
Table of Contents
EXHIBIT INDEX
Exhibit | ||
Number | Description of Exhibit | |
99.1 | Press Release |